Combination Vaccine with Reduced Antigen and Adjuvant Doses
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current combination vaccines often contain high levels of aluminium salts and antigens, which raise concerns for patient safety and compliance, and may not be optimized for reduced doses without compromising immunoprotective effects.
Innovation Solution
Development of combination vaccine compositions with reduced amounts of aluminium and antigens, including aluminium-free options, using oil-in-water emulsion adjuvants and adsorbed TLR agonists to maintain immunogenicity and immunoprotective effects, while allowing for fewer doses in infant immunization schedules.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high amounts of aluminium salts are used as adjuvants in combination vaccines, then immunogenicity is improved, but patient safety concerns increase
Solution Approach 1:
The patent applies parameter changes by systematically reducing the aluminium content from conventional levels (0.3-0.85 mg Al+++ per unit dose) to lower levels (0.03-0.2 mg Al+++ per unit dose), and ultimately to aluminium-free formulations. This parameter transformation maintains immunogenicity through optimized antigen combinations and dosing strategies while eliminating safety concerns associated with high aluminium exposure
Solution Approach 2:
The patent extracts and removes aluminium salts from the vaccine formulation entirely in certain embodiments, creating aluminium-free combination vaccines. This extraction eliminates the harmful adjuvant while preserving immunogenicity through alternative formulation strategies, directly resolving the contradiction between adjuvant efficacy and patient safety
2Reliability
If high amounts of antigen are used in combination vaccines, then immunoprotective effect is improved, but vaccine complexity and dosage requirements increase
Solution Approach 1:
The patent applies partial action by using reduced amounts of each individual antigen component in the combination vaccine. Rather than including full doses of multiple antigens that would create complexity, the formulation uses optimized lower doses of each antigen (e.g., reduced diphtheria, tetanus, pertussis, Hib, polio, and hepatitis B components) that collectively provide adequate immunoprotective effect while simplifying the overall vaccine composition
Solution Approach 2:
The patent merges multiple antigen components into a single integrated combination vaccine formulation. By combining reduced doses of six different antigens (diphtheria, tetanus, pertussis, Hib, polio, and hepatitis B) into one cohesive product, the patent reduces the number of separate injections required, simplifying the vaccination schedule and improving compliance while maintaining comprehensive immunoprotective coverage
3Reliability
If multiple injections are required for pediatric vaccination, then adequate immunization coverage is achieved, but patient compliance decreases
Solution Approach 1:
The patent merges six separate vaccine components into a single combination vaccine formulation, reducing the number of injections from six separate shots to one integrated injection. This merging maintains comprehensive immunization coverage against diphtheria, tetanus, pertussis, Hib, polio, and hepatitis B while dramatically improving patient compliance by eliminating repeated needle sticks
Solution Approach 2:
The patent creates a multi-functional vaccine that simultaneously provides protection against six different pathogens through a single administration. This universal approach allows one vaccine formulation to perform multiple immunization functions, achieving broad immunization coverage while simplifying the vaccination process and improving ease of operation for pediatric patients
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution achieves comparable immunogenicity and immunoprotective effects with lower aluminium and antigen doses, enhancing patient safety and compliance, and reduces the number of doses required in infant immunization schedules without compromising efficacy.
Implementation Method 1
an aluminium salt adjuvant
Implementation Method 2
oil-in-water emulsion adjuvant
Data Source
AI summary
Combination vaccine compositions as well as methods for their manufacture have a relatively low amount of antigen and/or a relatively low amount of aluminium, but they can nevertheless have immunogenicity which is comparable to combination vaccines with a relatively high amount of antigen and/or a relatively high amount of aluminium. Aluminium-free combination vaccine compositions are also provided e.g. compositions which are adjuvanted with an oil-in-water emulsion adjuvant.